A newly generated neutralizing antibodies from the team of Prof Florian Klein offers a new approach in the treatment of HIV infection. Prof Florian Klein is Director of the Institute of Virology of the University Hospital Cologne and working as a scientist in the German Center for Infection Research (DZIF). This study was a collaborative study – a team of Florian Klein collaborated with researchers at the Rockefeller University in New York and the University Hospital Cologne. This study and its clinical trials were published in the journal Nature and Nature Medicine.
Antiretroviral drugs are effective for the management of HIV infection as they encourage the rapid development of viral agents. These drugs must be administrated in combination. The recent study investigated the administration of a combination of the antibodies such as 3BNC117 and 10-1074 in more than 30 HIV-infected patients. These trials were processed in two different groups. The second group, they tried the combination on the patients who stopped their treatment with antiretroviral drugs.
The newly approved drugs are active inhibitors which require daily and life-long doses. The antiretroviral drugs are neutralizing antibodies have long lives and directly target the virus. Dr. Henning Grüll, the co-author of both the research and physician at the Institute of Virology of the University Hospital Cologne said, these clinical trial highlights that prescribing a combination of the antibodies has potential to maintain long-term control of HIV.
Prof Florian Klein said that the success of these studies at the University Hospital Cologne is collaborative results of the studies from Infectious Diseases Research Group and Infectious Diseases Outpatient Clinic. The future clinical trials will be investigating the additional approach using broadly neutralizing antibodies in HIV infection. These studies are being conducted at the DZIF site in Cologne.